The Defense Health Agency is looking for potential sources of research and development services as part of the agency’s follow-on Omnibus IV Medical R&D contract, Bloomberg Government reported Monday.
BGOV estimates the potential 10-year recompete award to have a ceiling value of $500M to cover a range of contract activities including information technology support, administrative services, logistics services and medical support.
Omnibus IV will include task orders for research, regulatory and translational assistance to support DHA initiatives aimed at improving force health readiness and rehabilitation, DHA said in the draft request for proposals posted Friday on the beta SAM website.
The indefinite-delivery/indefinite-quantity contract, which will replace the current Navy Medicine Omnibus III contract issued in 2012, will have a five-year base period and a five-year extension option, according to the solicitation.
BGOV data shows that Booz Allen Hamilton (NYSE: BAH), the top awardee for the incumbent contract, accounts for $100M in obligations.
Work under the new award is slated to commence in July 2021 and take place in various locations within and outside the continental U.S.
DHA will accept responses to the draft RFP through Nov. 30.
